Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Introduction

GlobalData, the industry analysis specialist, has released its new report, “Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Gallbladder Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Gallbladder Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gallbladder Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Gallbladder Cancer Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gallbladder Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gallbladder Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gallbladder Cancer Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Gallbladder Cancer Therapeutics market

Highlights

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gallbladder Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gallbladder Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Gallbladder Cancer Therapeutics market landscape? – Identify, understand and capitalize.

Report Highlights
AstraZeneca PLC
Simcere Pharmaceutical Co. Ltd.
[Studien Infos ausblenden]

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Gallbladder Cancer Therapeutics - Introduction 6
2.1 Overview 6
2.2 Epidemiology 7
2.3 Etiology 7
2.4 Pathophysiology 8
2.5 Signs and Symptoms 8
2.6 Diagnosis 8
2.6.1 Physical exam and history 8
2.6.2 Ultrasound exam 8
2.6.3 Liver function tests 8
2.6.4 Carcinoembryonic antigen (CEA) assay 8
2.6.5 Cancer antigen 19-9 (CA 19-9) assay 8
2.6.6 CT scan (CAT scan) 9
2.6.7 Blood chemistry studies 9
2.6.8 Chest x-ray 9
2.6.9 MRI (magnetic resonance imaging) 9
2.6.10 ERCP (Endoscopic Retrograde Cholangiopancreatography) 9
2.6.11 Biopsy 9
2.6.12 Laparoscopy 9
2.6.13 PTC (Percutaneous Transhepatic Cholangiography) 10
2.7 Staging 10
2.7.1 TNM Classification 10
2.7.2 Treatment Options Based on the Extent of Cancer 11
2.8 Treatment 11
2.8.1 Surgery 12
2.8.2 Chemotherapy 12
2.8.3 Radiation therapy (RT) 12
2.9 Chemotherapy Regimens 12
2.10 GlobalData Pipeline Report Guidance 13
3 Gallbladder Cancer Therapeutics - Market Characterization 14
3.1 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Global 14
3.2 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Global 16
3.3 Gallbladder Cancer Therapeutics Market Size (2005-2010) - US 18
3.4 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The US 19
3.5 Gallbladder Cancer Therapeutics Market Size (2005-2010) - The UK 20
3.6 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The UK 21
3.7 Gallbladder Cancer Therapeutics Market Size (2005-2010) - France 22
3.8 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - France 23
3.9 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Germany 24
3.10 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Germany 25
3.11 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Italy 26
3.12 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Italy 27
3.13 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Spain 28
3.14 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Spain 29
3.15 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Japan 30
3.16 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Japan 31
3.17 Drivers and Barriers for the Gallbladder Cancer Therapeutics Market 32
3.17.1 Drivers for the Gallbladder Cancer Therapeutics Market 32
3.17.2 Barriers for the Gallbladder Cancer Therapeutics Market 32
3.18 Key Events Impacting the Future Market 33
3.18.1 Opportunity and Unmet Need 33
3.19 Key Takeaway 34
4 Gallbladder Cancer Therapeutics Market - Competitive Assessment 35
4.1 Overview 35
4.1.1 Strategic Competitor Assessment 35
4.2 Profiles of the Commonly Used Products in the Gallbladder Cancer Therapeutics Market 36
4.2.1 Gemcitabine 36
4.2.2 Gemcitabine and Cisplatin 36
4.2.3 Gemcitabine and Oxaliplatin (GEMOX) 36
4.2.4 Gemcitabine and Capecitabine 36
4.2.5 5-Fluorouracil (5-FU) and Cisplatin 36
4.3 Key Takeaway 37
5 Gallbladder Cancer Therapeutics Market - Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Gallbladder Cancer Pipeline Analysis - Pipeline by Clinical Phases of Development 38
5.3.1 Gallbladder Cancer Therapeutics - Phase II Pipeline 39
5.3.2 Gallbladder Cancer Therapeutics - Phase I/II Pipeline 39
5.3.3 Gallbladder Cancer Therapeutics - Phase I Pipeline 39
5.4 Gallbladder Cancer Pipeline by Mechanism of Action 40
5.5 Gallbladder Cancer Technology Trends Analytical Framework 41
5.6 Profiles of Phase II Drugs under Clinical Development 42
5.6.1 Caprelsa (vandetanib) 42
5.6.2 Sinofuan (fluorouracil implant) 42
5.7 Key Takeaway 42
6 Gallbladder Cancer Therapeutics - Clinical Trials Mapping 43
6.1 Clinical Trials by Country (US, EU5 and Japan) 43
6.2 Clinical Trials Mapping by Phase 44
6.3 Clinical Trials Mapping by Trial Status 45
6.4 Overall Sponsors 46
6.5 Prominent Sponsors 47
6.6 Top Companies Participating in Gallbladder Cancer Therapeutics Clinical Trials 48
7 Gallbladder Cancer Therapeutics - Strategic Assessment 49
7.1 Future Market Competition Scenario 49
8 Gallbladder Cancer Therapeutics - Future Players in The Market 50
8.1 Introduction 50
8.2 Company Profiles 51
8.2.1 AstraZeneca PLC 51
8.2.2 Simcere Pharmaceutical Co. Ltd. 52
9 Gallbladder Cancer Therapeutics- Appendix 54
9.1 Definitions 54
9.2 Acronyms 54
9.3 Research Methodology 55
9.3.1 Coverage 55
9.3.2 Secondary Research 56
9.3.3 Forecasting 56
9.3.4 Primary Research 58
9.3.5 Expert Panel Validation 59
9.4 Contact Us 59
9.5 Disclaimer 59
9.6 Bibliography 59
[Inhaltsverzeichnis ausblenden]

1.1 List of Tables
Table 1: Survival Rates of Gallbladder Cancer in Various Stages 7
Table 2: Prevalence of Gallbladder Cancer in Major Markets 7
Table 3: Gallbladder Cancer, TNM Definitions 10
Table 4: Gallbladder Cancer, Stage Grouping 11
Table 5: Treatment Options Based on the Extent of Cancer 11
Table 6: Gallbladder Cancer Chemotherapy regimens 12
Table 7: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Table 8: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Table 9: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010 18
Table 10: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2010-2018 19
Table 11: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010 20
Table 12: Gallbladder Cancer Therapeutics Market, The UK, Forecast ($m), 2010-2018 21
Table 13: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 22
Table 14: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018 23
Table 15: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Table 16: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Table 17: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Table 18: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Table 19: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Table 20: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Table 21: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Table 22: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Table 23: Gallbladder Cancer - Phase II Pipeline 39
Table 24: Gallbladder Cancer Therapeutics - Phase I/II Pipeline 39
Table 25: Gallbladder Cancer Therapeutics - Phase I Pipeline 39
Table 26: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011 43
Table 27: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011 44
Table 28: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011 45
Table 29: Gallbladder Cancer Therapeutics - Clinical Trials, by Overall Sponsors, 2011 46
Table 30: Gallbladder Cancer Therapeutics - Clinical Trials by Prominent Sponsors, 2011 47
Table 31: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 48
Table 32: AstraZeneca - Gallbladder Cancer Pipeline 52
Table 33: Simcere Pharmaceutical - Gallbladder Cancer Pipeline 53
1.2 List of Figures
Figure 1: Anatomy of the Gallbladder 6
Figure 2: Magnetic Resonance Imaging 9
Figure 3: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Figure 4: Gallbladder Cancer Therapeutics, Market Share ($m), 2010 15
Figure 5: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Figure 6: Gallbladder Cancer Therapeutics, Market Share ($m), 2018 17
Figure 7: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010 18
Figure 8: Gallbladder Cancer Therapeutics Market, The US, Forecast ($m), 2010-2018 19
Figure 9: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010 20
Figure 10: Gallbladder Cancer Therapeutics, The UK, Forecast ($m), 2010-2018 21
Figure 11: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 22
Figure 12: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018 23
Figure 13: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Figure 14: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Figure 15: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Figure 16: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Figure 17: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Figure 18: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Figure 19: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Figure 20: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Figure 21: Gallbladder Cancer Therapeutics, Key Events Impacting the Future Market 33
Figure 22: Opportunity and Unmet Need in the Gallbladder Cancer Therapeutics Market, 2011 34
Figure 23: Gallbladder Cancer Therapeutics Market- Strategic Competitor Assessment, 2011 35
Figure 24: Gallbladder Cancer Therapeutics - Pipeline by Phase of Clinical Development, 2011 38
Figure 25: Gallbladder Cancer Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011 40
Figure 26: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework, 2011 41
Figure 27: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework - Description, 2011 41
Figure 28: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011 43
Figure 29: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011 44
Figure 30: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011 45
Figure 31: Gallbladder Cancer Therapeutics - Clinical Trials by Overall Sponsors, 2011 46
Figure 32: Gallbladder Cancer Therapeutics - Clinical trials by Prominent Sponsors, 2011 47
Figure 33: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 48
Figure 34: Gallbladder Cancer Therapeutics, Strategic Assessment, 2011 49
Figure 35: Gallbladder Cancer Therapeutics Market - Clinical Pipeline by Company , 2011 50
Figure 36: GlobalData Market Forecasting Model 58
[Tabellenverzeichnis ausblenden]